These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19585464)

  • 1. Insights into the anthrax lethal factor-substrate interaction and selectivity using docking and molecular dynamics simulations.
    Dalkas GA; Papakyriakou A; Vlamis-Gardikas A; Spyroulias GA
    Protein Sci; 2009 Aug; 18(8):1774-85. PubMed ID: 19585464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational insights into the interaction of the anthrax lethal factor with the N-terminal region of its substrates.
    Joshi M; Ebalunode JO; Briggs JM
    Proteins; 2009 May; 75(2):323-35. PubMed ID: 18831046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity.
    Tonello F; Montecucco C
    Mol Aspects Med; 2009 Dec; 30(6):431-8. PubMed ID: 19665472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of the anthrax lethal factor.
    Pannifer AD; Wong TY; Schwarzenbacher R; Renatus M; Petosa C; Bienkowska J; Lacy DB; Collier RJ; Park S; Leppla SH; Hanna P; Liddington RC
    Nature; 2001 Nov; 414(6860):229-33. PubMed ID: 11700563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exceptionally Selective Substrate Targeting by the Metalloprotease Anthrax Lethal Factor.
    Turk BE
    Adv Exp Med Biol; 2019; 1111():189-203. PubMed ID: 30267305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a Substrate-selective Exosite within the Metalloproteinase Anthrax Lethal Factor.
    Goldberg AB; Cho E; Miller CJ; Lou HJ; Turk BE
    J Biol Chem; 2017 Jan; 292(3):814-825. PubMed ID: 27909054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthrax lethal factor inhibitors as potential countermeasure of the infection.
    Kumar BV; Malik S; Grandhi P; Dayam R; Sarma JA
    Curr Top Med Chem; 2014; 14(17):1977-89. PubMed ID: 25262802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and biophysical characterization of the core protease domain of anthrax lethal factor.
    Gkazonis PV; Dalkas GA; Chasapis CT; Vlamis-Gardikas A; Bentrop D; Spyroulias GA
    Biochem Biophys Res Commun; 2010 Jun; 396(3):643-7. PubMed ID: 20438702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity.
    Panchal RG; Halverson KM; Ribot W; Lane D; Kenny T; Abshire TG; Ezzell JW; Hoover TA; Powell B; Little S; Kasianowicz JJ; Bavari S
    J Biol Chem; 2005 Mar; 280(11):10834-9. PubMed ID: 15644338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthrax lethal factor proteolysis and inactivation of MAPK kinase.
    Chopra AP; Boone SA; Liang X; Duesbery NS
    J Biol Chem; 2003 Mar; 278(11):9402-6. PubMed ID: 12522135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substrate recognition of anthrax lethal factor examined by combinatorial and pre-steady-state kinetic approaches.
    Zakharova MY; Kuznetsov NA; Dubiley SA; Kozyr AV; Fedorova OS; Chudakov DM; Knorre DG; Shemyakin IG; Gabibov AG; Kolesnikov AV
    J Biol Chem; 2009 Jul; 284(27):17902-13. PubMed ID: 19359249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor.
    Vitale G; Bernardi L; Napolitani G; Mock M; Montecucco C
    Biochem J; 2000 Dec; 352 Pt 3(Pt 3):739-45. PubMed ID: 11104681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metalloproteolytic activity of the anthrax lethal factor is substrate-inhibited.
    Tonello F; Ascenzi P; Montecucco C
    J Biol Chem; 2003 Oct; 278(41):40075-8. PubMed ID: 12888555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthrax toxin lethal factor domain 3 is highly mobile and responsive to ligand binding.
    Maize KM; Kurbanov EK; De La Mora-Rey T; Geders TW; Hwang DJ; Walters MA; Johnson RL; Amin EA; Finzel BC
    Acta Crystallogr D Biol Crystallogr; 2014 Nov; 70(Pt 11):2813-22. PubMed ID: 25372673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin.
    Bromberg-White J; Lee CS; Duesbery N
    Toxins (Basel); 2010 May; 2(5):1038-53. PubMed ID: 22069624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of domain II in toxicity of anthrax lethal factor.
    Liang X; Young JJ; Boone SA; Waugh DS; Duesbery NS
    J Biol Chem; 2004 Dec; 279(50):52473-8. PubMed ID: 15465830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational dynamics of the anthrax lethal factor catalytic center.
    Dalkas GA; Chasapis CT; Gkazonis PV; Bentrop D; Spyroulias GA
    Biochemistry; 2010 Dec; 49(51):10767-9. PubMed ID: 21121613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs.
    Bardwell AJ; Abdollahi M; Bardwell L
    Biochem J; 2004 Mar; 378(Pt 2):569-77. PubMed ID: 14616089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of high-throughput assay of lethal factor using native substrate.
    Kim J; Choi MK; Koo BS; Yoon MY
    Anal Biochem; 2005 Jun; 341(1):33-9. PubMed ID: 15866525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors.
    Zhang X; Amin EA
    J Mol Graph Model; 2016 Jan; 63():22-8. PubMed ID: 26615468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.